SPIA
GTBP icon

Steward Partners Investment Advisory’s GT Biopharma GTBP Stock Holding History

Steward Partners Investment Advisory’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1
Closed -$198 – 7222
2021
Q1 		$198 Buy
+1
New +$175 ﹤0.01% 3372

Other funds holding GTBP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SCP
Silverleafe Capital Partners Germantown, Tennessee $367M AUM 37.49% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Steward Partners Investment Advisory's GTBP Position: Q2 2021 in Review

Steward Partners Investment Advisory sold out of GT Biopharma (GTBP) in Q2 2021, closing a stake of 1 share — an estimated $198 sold.

Steward Partners Investment Advisory first reported a position in GTBP in Q1 2021 and held it in 1 quarter. The position peaked at $198 in Q1 2021. 49 funds tracked by Wall St. Rank hold GTBP as of Q2 2021.

  • Steward Partners Investment Advisory reported no remaining GT Biopharma position as of Q2 2021 after selling out during the quarter.
  • Steward Partners Investment Advisory sold 1 GT Biopharma share in Q2 2021, an estimated $198.
  • Steward Partners Investment Advisory first reported a position in GT Biopharma in Q1 2021 and held it in 1 quarter.
  • Steward Partners Investment Advisory's GT Biopharma position peaked at $198 in Q1 2021.
  • 49 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2021.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2021, filed 13 Aug 2021.